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ABSTRACT Understanding the mutual interactions of bacterial and phage populations in the environment of a human 
or animal body is essential in any attempt to influence these complex processes, particularly for rational phage therapy. 
Current knowledge on the impact of naturally occurring bacteriophages on the populations of their host bacteria, and 
their role in the homeostasis maintenance of a macro host, is still sketchy. The existing data suggest that different 
mechanisms stabilize phage-bacteria coexistence in different animal species or different body sites. The defining set 
of parameters governing phage infection includes specific physical, chemical, and biological conditions, such as pH, 
nutrient densities, host prevalence, relation to mucosa and other surfaces, the presence of phage inhibiting substances, 
etc. Phage therapy is also an ecological process that always implies three components that form a complex pattern of 
interactions: populations of the pathogen, the bacteriophages used as antibacterial agents, and the macroorganism. 
We present a review of contemporary data on natural bacteriophages occuring in human- and animal-body associated 
microbial communities, and analyze ecological and physiological considerations that determine the success of phage 
therapy in mammals. 
KEYWORDS bacteriophages, phage therapy, human body microbiota, animal body microbiota, bacteriophage ecology
ABBREVIATIONS GIT – gastro-intestinal tract, PFU – plaque-forming unit, which corresponds to a one viable bac-
teriphage particle, if the efficiency of infection in these conditions and in this strain is close to 1; CFU – colony-forming 
unit, which corresponds to a one viable bacterial cell.
INTRODUCTION
The use of bacteriophages as antibacterial agents was first 
suggested by one of the scientists who discovered bacteri-
ophages. F. D’Errele was the first to use a phage preparation 
to treat a severe case of child dysentery in 1919, only two 
years after the publication of his first article, which reported 
the discovery of bacterial viruses [1, 2]. The therapeutic use 
of phages in Western medicine spread widely in the late 30s–
early 40s, but it was subsequently almost completely forgot-
ten because of highly unstable results, which was due to in-
sufficient development of phage biology, phage production 
methods, the storage and use of drugs,  and on the other hand, 
to the triumph of antibiotic treatment of bacterial infections, 
which seemed a simpler and better solution to the clinical 
problems in that field [2]. Nevertheless, the development and 
use of therapeutic phage preparations never stopped in the 
Soviet Union, as well as in Poland and the Czech Republic. 
The vast experience accumulated in those countries indicates 
that phage-based drugs are effective and safe. Today, mass-
production of such antibacterial drugs continues in Russia 
and Georgia (where F. D’Errele personally took part in the 
establishment of the Bacteriophage, Microbiology and Vi-
rology Institute (now named after G. Eliava) in the 1930s). 
In Poland therapeutic phage preparations are produced and 
used in a specialized center at the Institute of Immunology 
and Experimental Therapy in Wroclaw.
The continuing increase in occurence of drug-resistant 
strains of pathogenic microorganisms and the dramatic slump 
in the development and marketing of novel antibacterial 
agents have spurred renewed interest towards phage thera-
py in the last 20 years in both Russian and Western medicine 
[3, 4]. Several reviews on issues related to phage therapy have 
recently been published [2, 5, 6, 7]. 
Modern phage therapy mostly uses bacteriophages, which 
belong to the Caudovirales order (“tailed phages”). About 96% 
of all known phages belong to this group [8]. Tailed phages are 
divided into 3 families:
1. Podoviridae, which have a short noncontractile tail;
2. Siphoviridae, which have a long noncontractile tail; and
3. Myoviridae, which have a contractile tail. 
RNA-bearing phages from the Leviviridae family, as well 
as filamentous phages bearing a single-strand DNA belonging 
to Inoviridae family, are also of ecological importance. Levi-
viral virions have small (~26 nm) icosahedral particles, which 
encapsulate a single-strand RNA genome. The filamentous 
particles of inoviruses are molecules of circular single-strand 
DNA, which is covered by low-molecular-weight envelope 
proteins. 
Members of the other prokaryote virus families (currently 
there are 14 families defined by ICTV) are rarely encoun-
tered and probably do not play a major role in the microecol-
ogy of symbiotic populations in mammals. More details on the 
classification of bacteriophages and the biology of particular 
groups of these viruses can be found in [8] and [9].
Despite the fact that virulent phages (those which cannot 
integrate their genome into the bacterial genome and cannot 
form lysogenic strains) cause the death of all infected cells 
and, reproducing exponentially under certain conditions and REVIEWS
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killing a large number of sensitive bacteria,  these viruses 
stably coexist with their hosts in practically all known natural 
ecosystems [10]. This coexistence has continued throughout 
the whole history of the life on Earth [11], and the interac-
tions between bacteria and phages at the level of the popula-
tion are fairly complex and multifaceted; thus, the simplistic 
interpretation of phages as the “natural enemies” of bacteria 
is inaccurate. 
From the microbiologist’s point of view, an animal or hu-
man organism is a complex microcosm that includes several 
interconnected ecosystems located in various organs and re-
gions of the body [12] and is inhabited by more or less dense 
populations of microorganisms, including bacteriophages 
[13].
The role of bacteriophages in the microflora of the body is 
considered to be “significant,” but in reality, knowledge on 
the subject is scarce. The presence of phages in normal body 
microflora was demonstrated by the discoverer of phages, 
Felix D’Errele (see above). He discovered enterobacterial 
phages in human and animal faeces [1]. Nevertheless, nei-
ther qualitative nor quantitative methods for measuring the 
interactions of phage and bacterial populations in symbiotic 
microbial systems have been developed for even a single ani-
mal species.  The understanding of the peculiarities of eco-
logico-physiological interactions in the tri-partite system of 
“bacteria-phages-macroorganism” must form the theoretical 
groundwork for controlling this system, including the appli-
cation of exogenous phage preparations which will eliminate 
unwanted bacterial populations. 
This review analyzes the current ideas on the ecology of 
bacterial viruses in human and animal microbial systems, 
the mechanisms of direct interaction between endogenous 
and exogenously applied phage particles and between these 
phages and the cells and organs of a macroorganism. Also we 
briefly discuss  the key theoretical principles underlying the 
therapeutic use of phage preparations.
BACTERIOPHAGES IN THE NORMAL MICROFLORA OF A BODY
The quantity and variety of phages in animal microflora. 
The bulk of articles on this subject study bacteriophages 
inhabiting the digestive tract of mammals (see further), in-
cluding the colon (and feces), the rumen (for ruminants) and 
forestomac (for marsupials) microflora [14], where phages 
are the most abundant free viral particles [13– 26]. Interest-
ingly, most of the RNA-bearing viruses in human feces are 
plant viruses particles, which are ingested with food [27]. 
The presence of free viral particles in the lungs or on the skin 
of animals has yet to be established. Yet several pathologi-
cal conditions, such as mucoviscidosis, are characterized by 
the simultaneous presence of phages and bacteria, including 
Pseudomonas aeruginosa [28]. Surprisingly, free virus parti-
cles have not been detected in the mouth [29].
Since the symbiotic populations of the human and animal 
gastro -intestinal tracts (GIT) include several hundred species 
(and thus up to a 1,000 strains) of bacteria and archaea, each 
of which is a potential target for phage infection, the majority 
of phages that inhabit the organism cannot be studied using 
culturing methods. However, the use of direct methods of 
analysis, such as extraction and purification of noncultutable 
viral populations from different regions of the GIT and their 
analysis by light and electron microscopy, electrophoretic 
separation and metagenomics, has allowed researchers to as-
sess the representation and variety of phages in microbial 
populations. A detailed analysis of these studies is beyond the 
scope of this article; they are comprehensively reviewed in 
[13]. Notably, the concentration of free virus particles in the 
colon region and the rumen of ruminant animals is estimated 
at about 108–1011 particles per milliliter. The number of dis-
tinct morphological types is estimated to range from tens to 
hundreds; and the number of distinct genotypes, from several 
hundred to 1,200 [13]. The overall number of phages and the 
ratio between the different species can change considerably 
during the course of time. Issues of whether certain types of 
phages are associated with certain animal species, and the 
biological geography of phages associated with animals and 
humans still remain obscure. 
CULTURABLE BACTERIOPHAGES IN THE NORMAL 
MICROFLORA OF ANIMALS AND HUMANS 
Bacteriophages usually have a very narrow range of host spe-
cificity; the infectivity of each phage is usually limited by a 
specific range of bacterial strains, which belong to a single or 
several closely related species of bacteria. However, in certain 
cases phages can infect bacteria from different species and 
even different genera. F. D’Errelle (1921) first suggested that 
the isolation of Yersinia pestis  phages from rat fecal matter 3 
months after the end of a plague epidemic can be attributed 
to the growth of these viruses in bacteria of different spe-
cies (in our view, it can be also explained by the persistence 
of Yersinia in rats). A recent study reported the persistence 
of vibriophages in oysters, in absence of the host during the 
winter period [30]; the authors suggested that vibriophages 
can use alternative host(s). Thus, the multi-species or multi-
genus specificity of certain phages can be of ecological signifi-
cance in the symbiotic microflora of animals. Nevertheless, 
even closely related strains of the same species can differ in 
their sensitivity to phages. This means that the effect of a 
phage infection on different populations of various species or 
strains can vary significantly. Cultural methods are currently 
the only approach for studying the ecological interactions be-
tween phages and their hosts at the strain level.
There is a large number of studies which report the isola-
tion and characterization of certain bacteriophages, which are 
obtained from humans or animals. Bacteriophages of Strepto-
coccus bovis, S. durans, Prevotella bryantii, Bifidobacterium 
ruminale were extracted from the rumen of various species 
of ruminant animals [14, 31]. Fecal matter from humans and 
various animals was used to isolate phages of E. coli, Salmo-
nella, Bacteroides, Klebsiella and other bacteria [32–43]. In 
most cases, the phages were isolated using laboratory strains 
of the appropriate species, or using wild isolates obtained and 
characterized in advance during the course of a large body of 
studies which used phages as indicators of the fecal pollution 
in water.
The presence and titers of DNA coliphages vary consid-
erably between different animal species and even between 
individual animals, which is consistent with the fact that a 
noncultivatable viral community is highly variable [44, 45]. 
However, there are no reports on the specific association of 
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cies of animal. In contrast to this, the presence of F-specific 
RNA (F-RNA) coliphages (Leviviridae family) in animal fecal 
matter exhibits a certain species-specificity. These bacteri-
ophages can be divided into 4 genotypic groups, which can 
also be distinguished serologically. The occurrence of specific 
serotypes can vary considerably between different species 
of animals: horse fecal matter, for instance, rarely has any 
F-RNA phages, while more than 70 % of chicken droppings 
samples show high titers of these viruses (105–107 PFU×g-1). 
Only 10–20 % of human fecal matter samples contain F-RNA 
phages, but groups II and III are most often present in these 
samples (> 80 % from the overall number of isolates), as op-
posed to other animals, in which groups I and IV are found 
with about the same frequency [33, 39, 42, 46]. Currently, 
there are no satisfactory explanations of this type of associa-
tion. 
The detection of a possible association between several ge-
netic subgroups in the known genera of tailed bacteriophages 
and their macro-host species may be complicated by the fact 
that simple and productive methods for the selective extrac-
tion of genetically related phages from wild samples have not 
yet been developed. Nearly selective isolation of phages relat-
ed to T-even phages from the fecal matter of a patient suffer-
ing from pediatric diarrhea in Bangladesh was observed when 
using E. coli K803 strain as a  test culture in [47]. Inoculation 
of a lawn of the enteropathogenic E. coli O127:K63 strain led 
to the isolation of a completely different set of phages, all of 
which were members of the Siphoviridae family. 
STUDY OF ENTEROBACTERIAL INDIGENOUS PHAGES
Furuse et al. [36] discovered that the amount of titers of col-
iphages in the fecal matter of healthy people is usually low 
and that the pool of free viral particles is usually formed by 
temperate phages. These data indicate that phage particles 
in the intestines of healthy people are produced mainly via 
spontaneous induction of lysogenic bacteria. Thus, the re-
production of phages in lytic cycle is of limited importance 
to the ecology of coliform bacteria in the human intestine. 
As opposed to healthy people, some patients suffering from 
internal diseases or leukemia exhibited an elevated number 
of titers of coliphages, and a major portion of isolated bacte-
riophages are virulent phages [46]. In several patients, the 
growth of coliphage titers correlated with the severity of the 
patient’s condition. 
The data presented in [36] are in agreement with the fact 
that attempts to isolate coliphages from dog fecal matter by 
using indigenous strains of E. coli had no success [48]. Using 
more than 500 indigenous strains of E.coli as hosts, 6 sam-
ples of fecal matter from domestic dogs were screened for 
coliphages, but none were found. Only one of the samples 
yielded phages, which were active on the laboratory E. coli 
strain C. On the other hand, 16 dogs kept in an animal kennel 
were found to have various titers of coliphages from 0 to 107 
PFU×g-1. The authors suggest that the absence of phages in 
domestic dogs was due to their isolation from their kin and 
the “too clean” living conditions. Recontamination by fecal 
microorganisms is understandably limited for humans as well, 
which can partly account for the above-cited results [36]. 
The results of our recent study, which used horses as 
a model [15, 49], are in contradiction with the data in [46]. 
The celluloseolytic microbial community in the horse colon 
is highly complex and can include more than 500 species of 
bacteria, archaea, and also fungi and protozoa. In contrast to 
the rumen community, the microbial biomass of the colon is 
not subjected to further enzymatic hydrolysis and is excreted 
with the fecal matter in practically unchanged conditions. 
The physico-chemical conditions in the equine colon seem to 
be more stable than that of most other animals, since the av-
erage time of cellulose-rich food (grass) digestion is 72 hours, 
which is considerably more than the time windows between 
eating or defecation events [50].
In order to study the ecological interactions between col-
iphages and their hosts under these conditions, we monitored 
the dynamics of coliphage and coliform bacteria titers in 4 
animals taking samples every 48 hours. Phage titer was meas-
ured using the laboratory E. coli test-culture C600. Study [36] 
analyzed 9 series of samples obtained from 19 healthy people 
at two week intervals and did not detect any significant tem-
poral changes of coliphage titers or variety. In horses we ob-
served significant changes in the phage titer (2–4 logarithmic 
units for different animals during the course of the 16-day 
observation period). However the titers of coliform bacteria 
were much more stable and fluctuated only slightly around 
5 × 105 CFU×g-1. The difference between coliphage dynamics 
in humans and in horses may be an indication of a more sig-
nificant role played by phage infection in the ecology of the 
latter’s enterebacterial ecology. 
We did not detect any correlation between the titers of col-
iform bacteria and coliphages in our animal group. This result 
may be due to the extremely high variety of E. coli strains 
and other bacteria which make up the coliform pool in horse 
intestines [51]. In order to differentiate between closely re-
lated isolates, which can however differ in their phage sensi-
tivities, we employed a simple scheme of PCR-fingerprinting 
[49]. Using this approach, we demonstrated that the pool of 
coliform bacteria present in the samples of horse fecal mat-
ter includes up to 1,500 individual strains (estimated using 
the nonparametric Chao1 criterion). We also estimated the 
share of coliform strains which were sensitive to a certain 
phage isolate from the same sample. On average, about 1-8% 
of the strains turned out to be sensitive. The variety of bac-
teriophages which display activity towards a specific indig-
enous strain of E. coli obtained from the same sample is usu-
ally very low and is limited to 1-2 genotypes distinguishable 
by restriction analysis. The variety of phages which could be 
detected by plating on the laboratory E. coli strain C600 was 
also limited; only 1–3 types in each of the samples studied. It 
seems that this results reflect the severe competition of the 
viruses for the available host cells. 
EFFECTS OF VIRAL INFECTION ON THE 
BACTERIAL POPULATIONS OF THE GIT
Microbial biomass can account for up to 54% of the hydrated 
mass of human feces. [52]. Coliform bacteria (> 80 % of which 
are usually represented by E. coli strains) are usually present 
in human and other animal feces in titers of about 105–108 
CFU×g-1 [39]. Streptococcus bovis is present in the ruminal 
fluid of sheep in concentrations of 106–107 CFU×ml-1 [14, 53]. 
These population densities are higher than needed for the 
exponential reproduction of phages (104 cells×ml-1 for most REVIEWS
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phage-host systems) [54]. Thus, some mechanisms that stabi-
lize the co-existence of phages and bacteria must exist.
We assume that coliphage infection is a selective factor 
which retains a high level of intraspecies variety of coliform 
bacteria in horse intestine limiting the chance for the few best 
competitors strains to outgrow the others. On the other hand, 
the high variety severely limits the availability of host cells 
for each specific type of coliphage, thus stabilizing the whole 
system. The high degree of variety and the reticular organi-
zation of the system make direct differential monitoring of 
individual strains and their associated phage populations very 
difficult, thus preventing direct validation of this hypothesis. 
However, we discovered recently that the intraspecies vari-
ety of coliform bacteria experienced a severe reduction after 
peroral application of enrofloxacin for a prolonged period of 
time, due to a severe leg wound to a horse. The overall titer 
of coliforms remained at normal level (the dominant strains 
were resistant to the antibiotic). Currently, we are develop-
ing the idea of using such animals with an artificial decrease 
in the intraspecies variety of symbiotic coliforms as a model 
for studying bacteriophage ecology, since it will allow us to 
perform direct experimental tests to prove our hypothesis. 
Another approach to this problem is analyzing the formation 
of a normal microflora in newborn horse foal.
The observed structure of the intestinal coliform bacteria 
and coliphage community is in agreement with the results 
of mathematical and experimental modeling of communities 
consisting of bacteria and their phages living under condi-
tions allowing the co-evolution of both components [55–58]. 
The population of hosts exhibited an observable split into a 
multitude of genetic lines with varying phage sensitivities. 
In turn, the phages were selected for widening of their host 
variety, albeit at the price of absorption efficiency. Thus the 
initial two-part system became much more complex [57]. In-
teraction with bacteriophages can also facilitate the selection 
of bacterial strains bearing mutations of their mismatched 
base reparation genes, or other mutations that destabilize the 
genome [59, 60]. Such hypermutable strains have an advan-
tage only in rapidly changing conditions, where the possibil-
ity of obtaining new traits counterbalances the accumulation 
of deleterious mutations [61]. The presence of bacteriophages 
which are able to evolve in situ seems to be one of the types 
of such a variable selective pressure. The presence of a large 
number of hypervariable strains in natural enterobacterial 
populations has been demonstrated [62]. Thus, phage infec-
tion can facilitate the increase in phenotypic variety not only 
by direct selection of resistant strains, but also by supporting 
the hypermutable strains in the population.
Bacteriophage infection can play a certain role during the 
events that triggered in the horse GIT when it was over-
loaded with carbohydrates. A hypothesis has been advanced 
that certain toxins produced by the altered microflora found 
their way into the bloodstream and somehow, either directly 
or indirectly, caused lowered adhesion of the hoof epithe-
lium to the basal membrane. It was recently shown [63] that a 
rapid increase in the number of streptococcus of the S. bovis 
/ equinus group in the colon takes place 8–16 hours after the 
administering of oligofructane. However, the number of these 
bacteria dropped very rapidly afterwards. One of the possible 
explanations is a massive infection of the streptococci by the 
appropriate phages, similarly to the phage control mechanism 
during cyanobacterial water blooming [10].
The significant selective influence of natural phages was 
demonstrated on a population of Campylobacter jejuni in 
chickens. The amount of С. jejuni phages in the chicken’s ap-
pendix was negatively correlated to the degree of colonization 
by bacteria (an average of 105 CFU×g-1 in phage-containing 
samples, as opposed to 107 CFU×g-1 in samples where no 
phages were found) [64]. It later turned out that the pres-
ence of phages selects variants of C. jejuni bearing extensive 
rearrangements of the genome [65], which occur because of 
horizontal transfer or as a result of intragenomic inversions 
with breakpoints in two Mu-like prophages integrated into 
bacterial DNA [66]. In both cases, the variants which were 
sensitive to the phages had a considerable advantage in the 
colonization of broiler chickens. In the absence of phages, the 
population rapidly reverted to the sensitive phenotype. The 
authors suggested that the genomic rearrangements in C. je-
juni occurring in the GIT of the birds played the role of an 
adaptive mechanism that allowed the bacteria to survive the 
periods of phage activity and the consequent competition for 
resources. 
THE EFFECT OF ARTIFICIALLY INTRODUCED 
PHAGES ON GIT BACTERIA
Effective elimination of pathogenic bacteria from the GIT 
using phage preparations has been demonstrated in multi-
ple experiments on the therapeutic use of phages [2, 7]. The 
therapeutic effect of the phages can be limited to a decrease 
in the pathogen’s population down to a point when the im-
mune system can effectively control its reproduction. In some 
cases, even such low doses of phage as 102 PFU could prevent 
the development of an infection by artificial introduction of 
pathogenic E. coli [67]. It is noteworthy that these low dos-
ages were much less effective if they were administered af-
ter inoculation with the pathogen. This is an indication that a 
population of pathogenic bacteria is much more susceptible to 
phage attack before it has colonized certain protected regions 
of the intestine.
The impact of an artificially introduced phage cocktail 
was studied on resident and introduced populations of E. coli 
in mouse intestines [68]. The mice used in these experiments 
stably excreted E. coli at titers of about 106 CFU×g-1 of feces. 
This value varied slightly during the course of time, but the 
presence of natural coliphages was undetectable on the indi-
cator E. coli K803 strain, which was sensitive to all the phag-
es used in later experiments. The mice were treated with a 
phage cocktail (titer 107 PFU×ml-1) through their drinking 
water. These phages were summarily active against practi-
cally 100% of the resident strains, which were isolated from 
the animals before the experiment. Nevertheless, the impact 
of the externally introduced phages on the titers of coliform 
bacteria was insignificant, and the phages were incapable of 
sustained propagation by infection of the resident bacteria. 
The E. coli isolates obtained during the experiment exhib-
ited the same sensitivity pattern to the components of the 
cocktail, which ruled out a shift of the resident population 
towards the prevalence of resistant variants. However, the 
phages did effectively lower the amount of a sensitive E. 
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prior to the administering of the phage cocktail. This effect 
was accompanied by active replication of the phages in the 
intestine. However, the surviving portion of the population 
remained sensitive to the phages, which indicates the ex-
istence of certain niches in the mouse intestine where the 
bacteria are either physically or physiologically shielded 
from the phage infection. Since practically all of the resident 
population of normal mice is protected, these “shelters” can 
accommodate almost all the E.coli population in the mouse 
intestine by E. coli. Interestingly, mice obtained from the 
same animal care facility a year after the experiments had 
practically no E. coli in their intestines and were colonized 
by other species of enterobacteria [Brüssow, personal com-
munication]. This observation is in agreement with [69], 
which found that less than 20% of the 48 mice studied in the 
project bore resident E. coli in their GIT, while coliphages 
were present in minimal titers in those cases. The author 
suggested that one of the main reasons blocking the repro-
duction of coliphages in the GIT of mice is the absence of a 
sufficient population of hosts.
The production of phages in the intestine is also affected 
by the physico-chemical factors in the environment. Bile salts 
and carbohydrates, for instance, can have an inhibitory ef-
fect on the absorption of many coliphages [70]. This effect 
is negated by the expression of the Ag43 protein, which is a 
bacterial surface adhesin that promotes cell aggregation, for 
instance during the formation of biofilms. Ag43 synthesis is 
controlled via the phase-variation mechanism; thus, a phage 
infection can sometimes screen for cells that have a reduced 
ability to form biofilms. Notably, some phages of Bacteroides 
exhibited an opposite reaction to the addition of bile salts to 
the culture media, growing more effectively [71].
Growth in a biofilm on the surface of a mucous membrane 
or on food particles can play a major role in containing viral 
infection of bacteria in the GIT. Some data [72] seem to in-
dicate that E. coli populations in the mouse’s intestine are in 
great part made up of cells in a state of starvation, which are 
physiologically ill-suited for phage reproduction. The active-
ly reproducing share of the population may be located only 
in microcolonies on the mucous membrane of the intestine 
[73]. However, both of these studies used mice treated with 
streptomycin and artificially inoculated by a single E. coli 
BJ4 strain with a known phenotype. Moreover, the fact that 
the digestion processes of mice can vary significantly from 
those of larger animals is material. The metabolic rate of mice 
is much higher, and the food travels through the intestine 
much more quickly than in horses or humans. Furthermore, 
the ratio between the mucous membrane’s surface and the 
volume of the intestine is considerably higher, which facili-
tates a much more rapid uptake of nutrients. Thus, the issue 
of to what degree can mouse-obtained data be extrapolated 
onto larger animals remains to be settled. 
REGIONS OF THE BODY EXHIBITING LOWERED 
PHAGE INFLUENCE ON THE MICROFLORA
Current data suggest that phages can, at least in some ani-
mals, successfully overcome the physico-chemical barriers 
that prevent infection and effectively reproduce using resi-
dent hosts, thus constraining their populations. Taking into 
account the openness of the GIT ecosystem in terms of matter 
exchange with the outside environment, the significant role 
of bacteriophages comes as no surprise. However, the situa-
tion can be significantly different in other ecosystems of the 
organism, which are also densely populated by microbiota.   
Hitch et al. [29], for instance, could not isolate from the human 
oral cavity any phages that proved active towards indigenous 
bacteria, which made them conclude that the bacteria in that 
system are not significantly affected by phage infection. A 
satisfactory explanation has yet to be given to account for 
this fact. 
Some species of bacteria are abundant in the micro-
bial system of ruminant animals. S. bovis can be present in 
concentrations of 106–107 CFU×ml-1 [14, 53]; moreover, the 
whole S. bovis population of a sheep’s rumen can belong to 
the same phagotype [53]. The authors observed a rapid shift 
from the dominant strain to a different one, with a differ-
ent phagotype, but these processes were not coupled with 
the appearance of any bacteriophage able to lyse any of the 
above-mentioned strains in the rumen fluid [53]. Neverthe-
less, the presence of S. bovis phages in the rumen in titers of 
101–5×104 PFU×ml-1 variable in different individual animals 
was later demonstrated [74].
The ecology of ruminal streptophages was thoroughly 
studied by Tarakanov and coauthors in the 1970s-1980s. 
Sadly, most of the results published by these authors are con-
tained in hard-to-access journals and government reports, 
which is why we reference a book [14] that has a detailed re-
view of these studies. The authors detected S. bovis phages in 
the rumens of cows and sheep in titers of 101–104 PFU×ml-1. 
The results of carefully controlled field experiments showed 
that the peroral introduction of an S. bovis phage preparation 
(streptophagin) into cows led to an increase in the phage’s 
concentration by a factor of 104-105 , accompanied by a de-
crease in the amount of amilolytic bacteria, a decrease in the 
amilolytic and increase in the cellulolytic activity of the ru-
minal contents. These changes led to improvement of  yield 
and quality of  meat and milk produced by the treated ani-
mals. This was confirmed by detailed and well-documented 
research [14]. After the discontinuation of streptophagin, 
the phage titers returned to their initial values fairly quickly 
and the amount of amylolitic bacteria increased. These re-
sults were an indication that a preparation of a single type of 
phage could have a considerable impact on a large portion of 
the S. bovis population in rumens. This is in agreement with 
research [53] which demonstrates the low intraspecies variety 
of S. bovis in sheep rumens. On the other hand, it is obvious 
that an unknown factor prevents the effective reproduction 
of streptophages in the resident bacterial population in the 
system.
It was shown that tannic acid can inhibit phage reproduc-
tion in physiological concentrations by causing the precipita-
tion of phage particles [75]. Tarakanov [14] has demonstrated 
that the ruminal fluid of cows and acetic acid at physiological 
concentrations can both inactivate S. bovis bacteriophages. 
Notably, the sensitivity of different phages varied consider-
ably and was dependent on the concentration of the inacti-
vating agent used. Inhibition of phage activity in the rumen 
by various chemicals can play a major role in the control of 
the phage lysis of resident cells. This model is in agreement 
with the conclusion in study [76], which declares that the REVIEWS
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sometimes-observed mass lysis of bacterial biomass in the 
rumen is most probably a result of autolytic processes as op-
posed to phage infection.
The female and animal vaginas are also an ecological 
niche extensively colonized by bacteria. The bulk of the 
human vaginal microflora is made up of lactobacilli. Spe-
cies and strains of these bacteria vary among individuals 
[77], but normally each individual woman has 1–2 dominant 
strains [78]. The colonization density is relatively high and 
is about 106–107 CFU per vaginal swab. Thus, it can be as-
sumed that this population may be susceptible to mass lysis 
by bacteriophages. Yet all attempts to detect free phages in 
vaginal excretions have been unsuccessful [79], even though 
lysogenic lactobacilli strains are often found in the vaginal 
microflora [79, 80].
Even though the vagina is less susceptible to bacterial and 
viral exchange with the environment, excluding the exchange 
associated with sexual intercourse, studies of vaginal swabs 
of clinically healthy women often show an unexpected drop in 
the population of lactobacilli. In most cases, the normal flora 
regenerates on its own, but some individuals develop the so-
called anaerobic bacterial vaginosis, a disease during which 
the lactobacilli are replaced by anaerobic bacteria, such as 
Gardnerella vaginalis, Prevotella, Porphyromonas, Atapobium 
and Mobiluncus species. Epidemiologically, the disease seems 
to be a sexually transmitted disease [81, 82], even though the 
etiological agent has yet to be identified. In [81], A. Blackwell 
suggested that the reason for this disruption in lactobacilli 
flora, which in some cases leads to vaginosis, is a phage in-
fection. We hypothesize that this can be the case when the 
vagina is infected by lactobacilli lysogenic with respect to a 
phage active in the resident strain.
Lysis of host cells by moderate phages is usually pret-
ty infrequent: 10-1–10-2 [83–85]. Thus, the reproduction of 
these viruses in an ecological niche densely populated by the 
sensitive host strain usually happens via the lytic scenario, 
causing the death of the majority of resident cells. The latter 
may then be replaced by the descendants of the lysogenic 
strain which initially released the phage, and by newly lys-
ogenized bacteria or by other bacterial species. Such a sce-
nario was modeled mathematically and experimentally [83] 
on a model population of E. coli. Bearing in mind that the fre-
quency of a spontaneous induction of most lysogenic strains 
of vaginal lactobacilli is less than 10-8 PFU×cell-1 [79] in lab 
cultures, any factor that increases the induction frequency 
can increase the chance of an “ecological catastrophe” in the 
vaginal microflora. This can explain the strong epidemio-
logical correlation between smoking and the risk of bacterial 
vaginosis [81], since some substances of tobacco smoke can 
cause induction of prophages in lactobacilli [86]. However, 
the results in study [80] contradict Blackwell’s hypothesis 
[81]. The authors showed that lactobacilli prophages often 
lose their ability to induce and to reproduce in cells, seem-
ingly because they are selected in the presence of hydrogen 
peroxide, which is produced by many bacterial strains and 
is an activating agent for SOS-inducible prophages. A de-
tailed study of the temporal dynamics of lactobacilli strains 
in the vagina and of the lysogeny of these populations may 
provide the key to understanding the phage nature of vagi-
nosis cases. 
PHAGE–CELL INTERACTIONS, ECOLOGICALLY 
SIGNIFICANT EFFECTS
In many cases, isolates of enterobacteria (and probably other 
groups of microorganisms) obtained from the wild are par-
tially resistant to bacteriophages, which coexist with them. 
This resistance can manifest through a lowered inoculation 
efficiency of a specific phage, slow absorption, or a decreased 
yield of the phage, which may be due to the effects of the 
restriction-modification system [59, 87], and also of a whole 
range of specific resistance systems developed by bacte-
ria to counter some groups of phages [59, 88, 89]. Moreover, 
prokaryotes often have CRISPR-loci (clusters of regularly 
interspersed palindromic repeats) [90], which contain short 
sequences extracted from the bacteriophage genome, plas-
mids, or other alien DNA by an as-of-now-unknown mecha-
nism. The genes associated with CRISPR encode for proteins 
that form enzymatic complexes that can attack RNA or DNA 
molecules that include sequences identical to the so-called 
CRISPR spacers [91, 92]. Such systems allow bacteria of nu-
merous species to rapidly develop resistance to a specific 
phage strain, due to a decreased efficiency of infection. This 
resistance can however be circumvented by point mutations 
of the attacked sequences in question [28]. Quantative data 
that characterize the frequency and ecological significance 
of the systems that provide resistance to phages in microbial 
communities by affecting the intracellular development of 
the virus is still missing. This issue deserves special attention 
and study, since the mechanisms that cause abortive infec-
tion turn a portion of the cells that can absorb the phage into 
ecological traps, which accelerate the rate of decay of free 
phage particles considerably [94].
In a recent study by our group, only 1-4% of the coliform 
bacteria strains isolated from horse feces samples exhibited 
sensitivity after cultivation on phage agar prepared with 
phages extracted from the same series of samples from the 
same animal [49, Tarasyan, unpublished data]. However, 
these phages showed a considerably decreased inoculation 
efficiency (10-2–10-4) on lawns of some isolates [Tarasyan et 
al, manuscript in preparation]. In some cases, this effect is due 
to the ineffective absorption of the phage and can be circum-
vented by mutational or recombinational rearrangements of 
the phage’s adsorption apparatus. Interestingly, even closely 
related bacteriophages extracted from the same animal can 
have slightly different host ranges [49]. This seems to indicate 
the high in situ adaptation rate of the absorption apparatus. 
Thus, the level of isolation existing in the phage-host system 
can be severely underestimated. As a result, the populations 
of each distinct genetic line of phage exist in conditions of 
strictly limited numbers of available host cells. In some cases, 
the effective concentration of phages and their respective 
sensitive cells drop to such a low level that one can expect 
the extinction of the phage population. For instance, the con-
centration of bacteria in a horse feces sample in our exam-
ple mentioned above was 103–104 CFU×ml-1 [49, Tarasyan 
et al., unpublished data], which is below the minimal value 
needed for effective phage reproduction [54]. The concentra-
tion of the corresponding virulent phage was approximately 
102–105 PFU×ml-1, and this strain of phage, which can be 
identified by its restriction profile, persisted in the intestine 
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The mechanisms that stabilize the long-term coexistence of 
this virus and its hosts in the intestinal ecosystem remain un-
clear. Obviously, any adaptation of the bacteriophage that 
leads to an increase in the range of potential hosts will pro-
vide an immediate selective advantage. 
It is thought that some phages can carry “secondary” ad-
hesion proteins which are not directly connected with the ap-
paratus triggering the  DNA ejection . Many of these putative 
secondary adhesins contain immunoglobulin-like domains 
which are exposed on the surface of the heads, contractible 
covers of the tail, or on the ends of the collar fibers of the 
phages [95]. Some phages can carry domains on their collar 
filaments, which are similar to adhesins not related to immu-
noglobulins [96]. Data on whether such structures can affect 
the growth of phages in laboratory conditions is still missing, 
but in an ecological situation such as the one prevailing in an 
animal intestine, their role can be considerable. First of all, 
it can be achieved by increasing the probability of revers-
ible absorption after a phage particle has met with a sensi-
tive host-cell. The increased absorption rate is not beneficial 
in some ecological situations. When phages grow on a dense 
population of hosts immobilized on a viscous agar medium 
(for instance when cultured using the double-layer method), 
mutants that have a lower adsorption constant have a con-
siderable advantage and form plaques of larger size and with 
a higher number of virus particles [97]. This is due to the in-
creased rate of the viral diffusion into the viscous media filled 
with host cells, and into the surrounding liquid. The authors 
suggest that similar advantages for slowly absorbed phages 
can be important during development in biofilms and during 
the spread to new regions. The mechanisms that lead to the 
reversible loss of secondary adhesins (for instance some of the 
tail fibrils of many phages) can thus have a significant effect 
on the adaptation of phages to growth on bacterial biofilms 
or on plankton cells [97]. Notably, secondary fibrillar adhes-
ins can limit the diffusion of viscous media in several ways, 
including through an increase of the effective radius of the 
virus particles [97]. From this, it follows that preparations of 
phages obtained by cultivation in liquid or viscous media can 
be enriched with genetic variants optimal for the given mode 
of growth of the host population. The phages that form larger 
plaques may be less effective during growth in liquid media, 
since they exhibit a decreased level of absorption. These ideas 
should be taken into account when developing therapeutic 
phage preparations. 
The importance of lysogeny in the ecological interactions 
between phages and bacteria in symbiotic microbial com-
munities of animals requires further study. Some data [36] 
suggest that the induction of lysogenic bacteria is the main 
source of free coliphage particles in the intestine of healthy 
humans. However, most moderate coliphages isolated from 
the free phage particles pool of a sample of human or ani-
mal feces were members of the lambdoid phage group, while 
phages obtained by induction of lysogenic strains were mostly 
of the P2-like group [98]. In our recent study, all the phages 
extracted from horse feces and placed into one of the two 
groups by analyzing particle morphology and sequencing 
random portions of the genome turned out to be professional-
virulent phages [49, our unpublished data]. It is impossible 
to tell at this point whether this discrepancy in the results is 
indicative of a difference in the microbial systems of animals 
or is an artifact of the research method. 
Coliphages extracted from feces can often form metast-
able associations, which can be cultivated in laboratory con-
ditions for several passages. We have termed these pseu-
dolysogenic associations [A. Zimin, personal communication; 
our unpublished data]. The mechanisms which stabilize such 
associations are not always understood [99]. The most prob-
able explanation is that some portion of the cells in a colony 
is partially shielded from phages by polysaccharide material 
or due to the physiological condition of the cell. In some cas-
es, phages and bacteria can diverge during propagation on a 
agar medium, turning the pseudolysogenic association into a 
complex multicomponent community [our unpublished data]. 
Additional research is needed to understand whether pseu-
dolysogenic associations of virulent phages and their hosts 
play a significant role in the in vivo ecology of coliphages or 
whether this is only a laboratory phenomenon. 
THE PHARMACOKINETICS OF PHAGE PREPARATIONS
Penetration of bacteriophages into the internal environment 
of the organism. 
It is known that bacteriophages can penetrate into the 
bloodstream from the intestine and other regions of the 
body, which are inhabited by microorganisms, and then be 
transported by the blood flow [100, 101]. It seems that the 
presence of a certain number of natural bacteriophages in 
the blood is normal (the term “physiological viremia” was 
suggested for this phenomeneon) [101]. A recent study of the 
pharmacokinetics of three different phages on chickens [102] 
showed that peroral introduction of phage preparations led 
to the appearance of only one of the three phages in the liver 
and spleen in small quantities. This phage was also present 
in the lungs; however, it could be accidently inhalted by the 
birds since the phage preparation was instilled by a syringe 
into the mouth. So, this begs the conclusion that this way 
of administering the suspension does not lead to effective 
translocation of phages, despite the fact that this study used 
relatively high doses of phages (106, 107 and 108 PFU per in-
dividual). Phage administration was slightly more effective 
in aerosol form through the lungs. However, earlier studies 
[103–106] have demonstrated multiple cases of the effec-
tive introduction of therapeutic phages into the blood using 
rectal and peroral administration. Peroral use of the “Sex-
taphage” preparation (FSUE “Microgen”, Russia) yielded 
detectable bacteriophages in the blood an hour after admin-
istration [105]. Similar results were obtained when using this 
preparation as a rectal suppository [105, 106]. These studies 
do not report the phage dosages, listing only the volume of 
the preparation. They also do not report the phage titers in 
the blood, and there is no data on the differences between 
the penetrations of the various phages from the complex 
preparation. Notably, the rate of phage translocation from 
the GIT to the blood stream (similarly to bacteria) can vary 
significantly depending on the physiological conditions. 
An inflammation considerably increases the translocation 
of bacteria (and probably phages) from the intestine [12]. 
It is not yet known which specific phage traits affect their 
translocation through the mucosa. Probably, the transport 
is receptor-dependent and is executed as an active process REVIEWS
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by specialized cells of the immune system (М-cells, goblet 
cells) and possibly by epithelial cells of the intestine and oth-
er components of the GIT. Several studies have attempted 
to identify the amino acid sequences that are involved in 
the binding with the appropriate receptors. These studies 
used the phage display approach [107–110]. Libraries of 
random peptides exposed on the surface of the filamentous 
М13 phage (which normally exhibits ineffective transloca-
tion through the mucous membranes of the GIT) were in-
troduced into the GIT of experimental animals, after which 
the phages were extracted from the blood and internal or-
gans or from the appropriate tissues from the GIT itself, and 
the peptides that were exposed on their surface were se-
quenced. The results showed that peptides YPRLLTP [108] 
and CSKSSDYQC [110] facilitate phage transport, peptides 
LETTCASLCYPS and VPPHPMTYSCQY [109] enhance 
the binding to М-cells and to rat Payer patch tissue, and 
the LTHPQDSPPASA peptide stimulates the binding of the 
phage particles to the mucous membrane of the mouse in-
testine, which was damaged as a result of a strong systemic 
inflammatory reaction [107]. As opposed to the cited results, 
study [111] identified no significant effect of 7-amino acid 
peptides on the transport of the M13 phage from the mouse 
intestine into the bloodstream. It is quite possible that this 
result is due to the specifics of the experimental system used 
by the authors, or that 7 amino acid residues are not of suf-
ficient length for the effective binding with appropriate cell 
receptors on the intestinal mucous membrane of mice. Cur-
rently, there is data in the literature on attempts to select 
therapeutically promising phages (mostly so-called tailed 
phages) for their ability to effectively travel into the blood-
stream from the GIT. The success in selecting the phages 
that can circulate in the blood for prolonged periods of time 
(see further) gives hope that this procedure can be effective 
in some cases. Notably, numerous results indicate the high 
efficiency of phage translocation into the blood during rectal 
administration of the preparation [103, 105]. This phenome-
non is being exploited in therapeutic practice now. There are 
phage preparations on the Russian market that are sold as 
rectal suppositories (see above); however, the mechanisms 
of phage translocation from the rectum and the factors that 
influence this process deserve a more thorough analysis. 
Intramuscular or intraperitoneal administration of phag-
es leads to much more effective translocation into the blood 
and organs than peroral methods. Thus, data from [102] 
shows that 3 hours after intramuscular injection of 108 PFU 
of three types of phages into chickens, their concentrations 
in the spleen were 2×102– 3×104 PFU×ml-1 and 6×102 – 104 
PFU×ml-1 in the liver. During the following hours, the phage 
concentration dropped rapidly, and after 24 hours the phag-
es were practically eliminated. Of note were the interesting 
differences in the effectiveness of infiltration of bird organs 
by different types of phages injected at the same doses. In-
traperitoneal injection of 1011 PFU of phages (4 phages were 
tested) into mice resulted in a blood concentration of 5×108–
2×1010 PFU×ml-1 two hours after injection, which indicates 
the effective infiltration of the inner environment of the or-
ganism [112]. One of the earlier (but also one of the most rig-
orously performed) studies of the phage pharmacokinetics 
[113] showed the effective infiltration of Shigella dysente-
riae bacteriophages through the mouse’s hematoencephalic 
barrier. Intraperitoneal injection of ultrafiltration-purified 
lysates with phages led to an almost immediate appearance 
of phages in the blood. Infiltration of healthy animal’s brain 
tissues was recorded only in a few individuals on a small scale. 
On the other hand, mice infected with S. dysenteriae (inject-
ed intracerebrally with a dose exceeding DL95 %)  showed 
a rapid increase of the phage titer of up to 107–109 PFU×g-1 
in the brain tissue. During the following monitoring period, 
the phage titer in the brain decreased slower than that in the 
blood. The survival rate of mice that received 107–109 PFU 
of the phage was 72 % as opposed to 4 % in the control group, 
which received a heat inactivated phage preparation. 
THE DISTRIBUTION OF PHAGE PARTICLES IN THE 
ORGANISM AND THEIR ELIMINATION 
Early research in the 1920s-1930s [2] demonstrated that 
bacteriophages are eliminated from the bloodstream very 
rapidly. Mice that received intraperitoneal doses of phage 
[112] had very quick increases in blood phage titer (up to 1010 
PFU×ml-1), after which the titer decreased approximately 
by a factor of 103 after 12 hours and continued to decrease 
in a soft curve. The authors approximated this two-phase 
curve using the following equation: С = 3.525×109×e-0,753t + 
2.35×107×e-0,0997t, where С is  the concentration expressed in 
PFU×ml-1; t is the time, in hours; while the numeric param-
eters varied for the different types of phages. Some bacterio-
phages can be absorbed onto erythrocytes and leucocytes in 
the bloodstream [93, 114]. Thus, it is unclear if such seques-
tered phages can infect the targeted bacteria during phago-
therapy. Phage particles are most actively absorbed by the 
liver, where they quickly decay [102, 115]. Phages survive 
slightly longer in the spleen [2, 102, 116]. It seems that the 
reticuloendothelial system plays a major role in this process 
as opposed to the circulating phagocytes, since mice with 
cyclophosphamide-induced neutropenia exhibit only limited 
inhibition of phage elimination [112].
Phage particles are subjected to effective elimination by 
the reticulo-endothelial system. However, it is possible to se-
lect phage strains with altered surface proteins, which ex-
hibit a significantly increased half-life in the bloodstream 
(one amino acid substitution may suffice [117]), and such 
long-circulating mutants can remain in the bloodstream for 
up to more than a 1,000 times longer than the initial strain 
[117–119].
Excretion of phages with urine has been shown in many 
cases [104–106, Darbeeva, personal communication]. How-
ever, this mechanism does not seem to play a major role in the 
phage elimination process, since the concentration of viruses 
in urine is approximately 101–102 [106], and such excretion 
is insignificant. On the other hand, even this insignificant 
number of bacteriophages, which make their way into the 
urinoexcretory system, is sufficient to have a therapeutic ef-
fect in the treatment of urological infections by peroral ad-
ministration of phage preparations [104]. It is safe to assume 
that inflammation-mediated damage to the basal membrane 
of the Malpighian tufts  can lead to increased phage excretion. 
It is also possible that the phages find their way into urine 
not via filtration through the tufts, but also through transfer 
from the blood into the canal epithelium. The issue of phage 68 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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excretion with urine and the factors that regulate this process 
require further investigation. 
The production of antibodies specific to bacteriophages 
in patients can block the positive effect of phage therapy. 
Moreover, healthy people and patients who have never un-
dergone phage therapy also have a certain level of antiphage 
antibodes [120]. However, the available data shows that the 
presence of such antibodies has a weak correlation with the 
results of therapy [A. Gorski, personal communication, 2]. It 
is worth noting that not all of the antibodies which interact 
with the phage particle have a direct neutralizing effect. In 
order to have this effect, antibodies would have to interact 
with adhesins and, in the case of some phages, with other el-
ements of the tail. The production of specific high-affinity 
immunoglobulins of the IgG class takes several weeks; that 
is why this problem is of little significance for short courses 
of phage therapy. Moreover, the immunogenic potential of 
various phages is very different, and some bacteriophages re-
quire the use of adjuvants and repeated immunizations in or-
der to achieve a significant immune response. It is also worth 
noting that the amount of antigens in the therapeutic doses 
of purified bacteriophages is relatively low; for instance, 1010 
particles of Т4 phage contain only about 1 microgramm of 
protein (this calculation is based on the assumption that the 
mass of DNA and protein is approximately the same in tailed 
phages [121]).
IMMUNOBIOLOGICAL ACTIVITY OF PHAGE PARTICLES
The direct effect of certain phage particles on the immune 
systems of humans and animals has been demonstrated re-
cently by a research group led by prof. Gorski. It was shown 
that the viral particles of T-even bacteriophages lower the 
amount of the reactive oxygen species produced by neu-
trophils, which were induced by bacteria or endotoxin, and 
suppress the activation of T-cells, thus facilitating transplant 
tolerance. These phages also had a degree of antitumor effect 
[122–124]. The use of bacteriophage preparations in the treat-
ment of various infections associated with Staphylococci and 
E. coli was often accompanied with a significant drop in the 
amount of serum C-reactive protein, which is an important 
marker of inflammation. It seems that such a decrease cannot 
be explained only by the antibacterial effect of the phages 
and must be connected to the immunomodulating activity of 
the phage particles [5].
It was suggested that the binding of Т4 particles to eukary-
otic cells is mediated by the capsid apex protein gp24 (gene 
product), which contains the KGD amino acid motif related to 
the RGD motif  recognized by β3 integrins [101]. This binding 
can partially account for the immunosupressing and antitu-
mor effect of the Т4 phage in vivo and in vitro [125]. A mutant 
of the Т4 phage, which has no gp hoc capsid decorating pro-
tein, has an increased immunobiological activity [125], which is 
possibly due to the partial masking of the β3 integrin-binding 
motif by these proteins. Some phages have surface proteins 
that are structurally similar to the molecules involved in the 
signaling cascades of immunocompetent cells. A whole range 
of structural proteins of various phages have immunoglobin-
like [95] or collagen-like domains [126]. Study [24] noted the 
considerable increase in the concentration of phage particles 
on an ulcerated intestinal mucous membrane and hypothesized 
that the immunologic activity of phage particles can play some 
role in the pathological process in the case of Crohn’s disease. 
On the other hand, it is thought that natural phage populations 
can take part in the interaction between the lymphoid tissues 
of the intestine and the microflora; for instance in the suppres-
sion of the inflammatory effect caused by massive contact with 
an antigen [101]. However, as of today, there is no experimental 
data that characterize the interaction of the natural viral com-
munity with the immune system. 
DYNAMICS OF PHAGE–BACTERIA 
INTERACTION DURING PHAGE THERAPY
Physicians and microbiologists, who are not well informed 
on the theoretical basics of bacteriophage ecology and phage 
therapy, often hold the misguided opinion that the appear-
ance of even a limited number of phage particles specific to-
wards the target strain of pathogen in the area of the body 
colonized by these bacteria will trigger rapid phage reproduc-
tion, which will continue until the whole bacterial population 
is destroyed. These views are even expressed in some meth-
odological literature (which we do not reference for ethical 
reasons). However, the coexistence of phages and bacteria 
in the same ecotope is an often-seen phenomenon in nature 
[10], and it has been around since before the separation of eu-
karyota, bacteria, and archaea [11]. Moreover, the interaction 
between bacteria and their viruses is not always antagonistic 
on the population level. Furthermore, the activity of bacteri-
ophages can lead, under certain circumstances, to increased 
variety and overall metabolic activity of natural bacterial 
communities [10].
Currently, the standard procedure in phage therapy is to 
use only virulent phages; meaning those that can exclusievly 
reproduce in the course of a lytic cycle. During such a course 
of events, each infected cell is lysed after a certain period of 
time, called the latency period, releasing 50-200 and some-
times more phage particles. This results in an increase in 
phage particle concentration. In natural systems, however, 
the viral reproduction process is constantly countered by vi-
ral particle destruction and their elimination from the studied 
system. In the case of phage therapy, the major factors are 
phage consumption by the reticulo-endothelial system, their 
sequestration through association with erythrocytes, tissue 
cells or the extrarcellular matrix, their destruction as a result 
of adsorption on dead or specifically resistant cells (see above), 
as well as excretion from the organism with urine and feces. 
It is also worth noting that the reproduction of phages is usu-
ally localized in the infection center, while the spread of the 
phage’s descendants occurs throughout the whole organism. 
If the bacteriophage’s in situ reproduction rate is higher than 
the rate of the spread and (or) destruction, then the phage 
concentration will increase up to the depletion of the avail-
able host cells. This is called active phage therapy [127], and 
it is probably the working scenario during phage therapy of 
certain intestinal infections, including experimental ones. In 
these cases, one or several doses of phages are enough to cure 
the infection [2, 6, 7]. Cases where the concentration of phages 
must be maintained in order to suppress the growth of bac-
teria (see further) and large quantities of phages must be in-
troduced artificially, such as during the treatment of chronic 
diseases, are termed passive phage therapy [127]. Many real-REVIEWS
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world cases are combinations of these two scenarios.
Let us discuss the factors affecting the kinetics of the in-
teraction of the bacterial population with the phages during 
therapy. The limiting step in the lytic cycle of the bacterio-
phage is the adsorption of the virus’ particle on the surface 
of a bacterium, which usually results in the injection into the 
cell of the viral nucleic acid (for therapeutic phages, this is 
genomic DNA). The absorption process is mediated by highly 
specific recognition of the appropriate receptors on the cell’s 
surface by phage adhesins [128]. These receptors are usually 
liposaccharides, surface proteins, teichoic acids, the compo-
nents of the bacterial capsule, and other surface structural 
elements of bacteria. This recognition is a passive physical-
chemical process, which is dependent on the collision fre-
quency of phage particles and cells during Brownian motion 
[129]. This process is described by a kinetic equation of the 
second order, which means that its rate depends on the con-
centrations of the bacteria and the phage. Specifically, ln(P/
P0) = e-kCt, where Р is the amount of phage particles adsorbed 
up to the time point “t”; С is the concentration of bacterial 
cells, which does not change with the passage of time t; and 
k is an absorption constant (ml×min-1). All the differences in 
the phage diffusion, number of receptors on the cell’s surface, 
inhibition of absorption by the physico-chemical factors of 
the medium, etc. are all factored into the value of “k,” which 
is measured empirically for each case [129]. Under laboratory 
conditions, most tailed phages in liquid media have a k value 
of about (1.5–2.5)×10-9 ml×min-1.
It was discovered empirically that different phage-host 
systems have threshold values of host cell concentration, 
which are needed for “triggering reproduction” of the virus 
[54] (usually about 104  CFU×ml-1). In real natural ecosystems 
(including animal organisms), the host concentration thresh-
old needed to trigger phage reproduction (МТ) can be calcu-
lated as the concentration at which the number of phages ab-
sorbed during the time of the elimination of half the phages 
(t1/2) minus the length of the latency period (tlat) is enough to 
provide offspring numbering half of the initial population. 
Therefore, it is a cell concentration (C), for which P(t1/2-tlat) = 
0.5P0/Y, where Y is the yield of the phage per infected cells in 
these conditions (the death of some infected cells before the 
release of phage progeny must be factored into this value). 
When C exceeds the threshold MT value, phage production 
will exceed its elimination and, thus, the phage concentration 
in the system will increase. 
There is also a threshold value of phage concentration 
Сphage, which inhibits the growth of the bacterial population if 
exceeded [127]. For this value of Cphage (IT), half of the bacteria 
will become infected during the time of an average genera-
tion (under the condition that the phage concentration during 
this time remains constant). The growth of rapidly reproduc-
ing bacterial cultures is inhibited under laboratory conditions 
at phage concentrations of about 107 [127, 129] PFU×ml-1. This 
value has no practical importance for laboratory use, since in 
vitro С >> MT, and the rate of phage particle destruction can 
be ignored; thus viruses accumulate very rapidly, causing 
practically complete lysis of the bacterial culture. It is obvious 
that the in vivo use of phage preparations will create other 
ratios between these processes, which is why populations of 
pathogenic bacteria are rarely destroyed completely during 
phage therapy. Thus, it makes more sense to speak of reduc-
ing the numbers of the pathogen to levels at which the infec-
tion can be controlled by the immune system [127].
In real-world phage therapy, most bacterial populations 
colonize only specific niches in the organism, and a major part 
of the bacteria are in physiological states, which do not al-
low reproduction of phages, for instance in biofilm form [130]. 
Cells that inhabit a biofilm are in a condition different from 
that in a suspended culture [131], and the cell’s sensitivity to 
phages is lower [119, 132]. This is partially due to the limited 
diffusion in the matrix surrounding the bacteria in biofilms. 
Neverthelss, bacteriophages can infect cells that inhabit bio-
films [132, 133]; some viruses encode enzymes which can hy-
drolyze the matrix polysaccharides. Moreover, the appropri-
ate genes can be introduced into the phage genome by genetic 
engineering [134]. Notably, phage infection causes disruption 
in the structure of the biofilm, making the surviving cells 
more available to the immune system. Bacteriophages seem 
able to infect persister cells [135], which are one of the major 
causes of failure in antibacterial chemotherapy of such infec-
tions [136]. The spatial heterogeneity of a biofilm’s structure 
[131], and many other microenvironments in the human and 
animal organisms, can, as it seems, limit the spread of phage 
infection. Dead and stationary cells also restrict the phage 
expansion, since they can absorb phage particles. Thus, an 
active process at the micro-level is coupled with a passive 
process at the level of the whole organism. This effect can 
help explain the success in phage therapy of a range of in-
fections; for instance pseudomonal osteomyelitis [М. Kuteta-
ladze, personal communication], which cannot be effectively 
treated with antibiotics not because the pathogen is resistant, 
but because of the specific localization of the infection. Even 
though the infiltration of phages into the center of infection 
is limited, the possibility of local infective chain reactions is 
probably the major cause of success in the therapy. Moreover, 
stationary cells with reduced physiological activity can be in-
fected, even though they do not allow the phage to reproduce. 
The infection will then be delayed until these cells are acti-
vated [135, 136]. Thus, the combination of active and passive 
phage therapy is the most probable scenario during the treat-
ment of stable chronic infections. Such treatment requires 
prolonged courses of therapy, which can lead to patients be-
ing cured [5, 6]. Such cases require maintaining the phage 
concentration in the infection center for a prolonged time by 
administering new doses. The treatment of wound infections 
can be performed by using drainages with a constant flow of 
the phage preparation into the wound, or by using prepara-
tions that release phage particles slowly, such as the drug 
“Phagebioderm”, designed in the G. Eliava Tbilisi Institute 
for Bacteriophages, Microbiology and Virology [137].
It is obvious that phage-resistant mutant bacteria can 
emerge during phage therapy. However, it is important to 
note that we could not find any documented case of unsuc-
cessful phage therapy caused by the emergence of phage-
resistant mutants. This can be explained by the fact that such 
mutants often have altered cell surface structures which act 
as receptors for the appropriate phages. The physiological 
price of such resistance is usually reduced growth [10, 138], 
colonization ability [7, 65, 66, 139, see also section 3.3], and 
virulence [139].70 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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CONCLUSION
The accumulating genomic and structural data [11] point to 
the fact that bacterial and viral coexistence has been con-
tinuing for more than 2 billion years. The “rules of the game” 
that have emerged during this time are such that the pres-
ence of phages in natural systems not only has no negative 
effect on the variety and overall activity of the bacterial com-
munity, but also increases them considerably [10]. As more 
and more becomes known about the biology and ecology of 
bacteriophages, it becomes more apparent that the seem-
ingly simple idea of using the “natural enemies” of bacteria 
to fight infection, which was first tried in practice in 1919 
by Felix D’Errelle and by prof. Victor-Anri Hutinel [2], is a 
clever trick that should allow the complete suppression of one 
player (the bacterial population) and thus result in the elimi-
nation of the other player (the bacteriophage population). In 
order to achieve this goal through a rational approach (as op-
posed to an empirical one), it is important to understand the 
mentioned “rules of the game” in the ecological systems that 
are part of the human and animal organisms. 
The analysis of the specifics of phage ecology allows to un-
derstand the additional requirements for therapeutic phages 
(other than their host range and in vitro efficiency) that could 
help identify the directions phage therapy research ought to 
take in the 21st century. Among these promising directions, 
we can mention 1) improving the technology of therapeu-
tic phage selection, including developing and standardizing 
quick moderate-virulent tests, creating systems for typing 
potential therapeutic phages in order to allocate them to one 
of the known groups, as well as developing a methodology for 
analyzing phage genomes in order to asses their use in phage 
therapy; 2) creating databases and collections of character-
ized therapeutic phages, which can be used to quickly for-
mulate individualized phage cocktails adapted to the needs 
of an individual patient; 3) developing methods to control the 
translocation and spread of phages in the organism, including 
methods for providing long-term circulation of phages in the 
blood, and their infiltration into various tissues and organs, 
etc.; 4) developing methods for testing the infective poten-
tial on bacteria which are in various physiological conditions 
or which colonize various “shielded” ecological niches in the 
organism, such as resident bacterial populations in the intes-
tine, bacteria inhabiting biofilms, etc., developing methods for 
modifying these phage’s traits, including methods involving 
genetic engineering; 5) monitoring and controlling the immu-
nobiological activity of phages and targeted use of the ability 
of phage particles to interact with immune system cells; 6) 
using  certain bacteriophage proteins as therapeutic agents, 
such as phage lysines [140] and bacteriocins.
Moreover, further studies of the role of bacteriophages in 
the homeostasis of normal microflora and in the development 
of pathological phenomena may help identify new approaches 
to the therapeutic control of these processes.  
This work of the Laboratory for Viruses of Microorganisms 
of the RAS Microbiology Institute is supported by the Federal 
Science and Innovation agency (Government Contract 
№ 02.740.11.0313), RFBR (grant № 09-04-01482-а), the 
Federal Education agency and the RAS presidential program 
"Fundamental science for medicine". 
The authors thank M. Levina and E. Kulikov for critical 
reading of the manuscript.
REFERENCES
1. d’Herelle F. La bactériophage. Son rôle dans l’immunité. Paris. // 1921. Cited after Rus-
sian edition. 1926. Moscow – Leningrad : State Editor .
2. Sulakvelidze A., Kutter E. Bacteriophage therapy in humans. In: Bacteriophages: 
biology and applications. // Eds. Kutter E. and Sulakvelidze A. 2005. P. 381–436. Boca 
Raton: CRC Press.
3. Hawkey P.M., Jones A.M. // J Antimicrob Chemother. 2009. Sep; 64 Suppl 1:i3-10.
4. Livermore D.M. // J. Antimicrob Chemother. 2009 Sep; 64 Suppl 1:i29-36.
5. Gorski A., Miedzybrodzki R., Borysowski J., et al..//Curr. Opin. Investig. Drugs. 2009.10. 
P. 766–774.
6. O’Flaherty S., Ross R.P., Coffey A. // FEMS Microbiol. Rev. 2009.33, 801.
7. Sulakvelidze A. and Barrow P. Phage therapy in animals and agribusiness. In: Bacteri-
ophages: biology and applications. Eds. Kutter E. and Sulakvelidze A. 2005.P. 335–380. 
Boca Raton: CRC Press.
8. Ackermann H.W. 5500 // Arch. Virol. 2007.152. P. 227–243.
9. Calendar R. ed. The bacteriophages. 2nd edition, Oxford university press, New York. 
2006.746P.
10. Weinbauer M. // FEMS Microbiol Rev. 2004. 28: P. 127–181.
11. Bamford D. // Res. in Microbiol. 2003. 154. P. 231–236.
12. Domoradskii I. V., Hohoyev T.H., Kondrakova О.А. et al. //Rossiyskiy Himicheskiy 
Zhurnal. 2002. 46. p. 80–89.
13. Letarov A., Kulikov E. //  J. Appl. Microbiol. 2009. 107. С. 1–13.
14. Tarakanov B.V. Bacteriophagy phenomenon in ruminary animals. М.: Nauchniy Mir. 
2006. p184.
15. Kulikov E.E., Isaeva A.S., Rotkina A.S., Manykin A.A., Letarov A.V. // Mikrobiologiia. 
2007. 76. P. 271–278.
16. Tarakanov B.V. // Mikrobiologiia. 1971. 40. P. 544–550.
17. Tarakanov B.V. // Mikrobiologiia. 1971. 1971. 41. С. 862–870.
18. Alexander F., Davies M. E., Muir A. R. //Res Vet Sci 1970.11. P. 592–593.
19. Breitbart M., I. Hewson B., Felts J, et al. // J. Bacteriol. 2003. 185. P. 6220–6223.
20. Cann J. A., Fandrich S. E., Heaphy S. // Virus genes 2005. 30. P. 151–156.
21. Flewett T.H., Bryden A.S., Davies H. // J. Clin. Path. 1974. 27. P. 603–614.
22. Hoogenraad N.J., Hird F.J.R. //Aust. J. Biol. Sci. 1970. 23. P. 793–808. 
23. Hoogenraad N.J., Hird F.J.R., Holmes I., Millis F. //J. Gen. Virol. 1967. 1. P. 575–576, 
942–943.
24. Lepage P., Colombet J., Marteau P. et al. //Gut 57. 2008. P. 424–425.
25. Paynter M.J.B., Ewert D.L., Chalupa W. //Applied Microbiol. 1969. 18. P. 942–943.
26. Ritchie A.E., Robinson I.M., Allison M.J. Rumen bacteriophage: survey of morpho-
logical types. In: Microscopie electronique, ed. Favard P. 1970. Vol. 3.P. 333–334. Paris: 
Societe Francaise de Microscopie electronique (cited by Tarakanov, 2006).
27. Zhang T., Breitbart M., Heng Lee W. et al. // PLoS Biol. 2006. 4(1): e3C3.
28. Brouns S.J., Jore M.M., Lundgren M. et al. // Science. 321. 2008. P. 960–964.
29. Hitch G., Pratten J., Taylor P.W. // Lett in Applied Microbiol. 2004. 39. P.  215–219.
30. Comeau A.M., Buenaventura E., Suttle C.A. // Appl. Env. Microbiol. 2005. 71. P. 
5324–5331.
31. Klieve A.V. // Appl. Environ. Microbiol. 1991. 57. P. 3660–3663.
32. Calci K.R., Burkhardt IIIW., Watkins W.D., Scott. R.R. //Appl. Environ. Microbiol. 
1998. 64. P. 5027–5029.
33. Cole D., Long S.C., Sobsey M. // Appl. Environ. Microbiol. 2003. 69. P. 6507–6514.
34. Cornax R., Morinigo M.A., Gonzalez-Jaen F., Alonso M.C., Borrego J.J. // Zentralbl 
Bakteriol. 1994. 281. P. 214–224.
35. Dhillon T.S., Dhillon E.K., Chau H.C., Li W.K., Tsang, A.H. // Appl. Environ. Microbiol. 
1976. 32. P.  68–74.
36. Furuse K., Osawa J. Kawashiro R. et al.  // J. Gen. Virol. 1983. 64. P. 2039–2043.
37. Gantzer C., Henny J., Schwartzbrod L. // Int. J. Hyg. Environ. Health. 2002. 205. P. 
325–328.
38. Grabow W.O.K., T.E. Neubrech C.S Holrzhausen and Jofre. J. // Water Science and 
Technology. 1995. 31. P.  223–230.
39. Havelaar A.H., Furuse K., Hogeboom W.M. // J. Appl. Bacteriol. 1986. 60. P. 55–262.
40. Lusiak-Szelachowska M., Weber-Dabrowska B., Gorski A. // Pol. Merkur. Lekarski. 
2006. 124. P. 381–383.
41. Muniesa M., Moce-Llivina L., Katayama H., Jofre J. // Antonie Van Leeuwenhoek. 
2003. 83. P. 305–315.
42. Schaper M., Jofre J., Uys M., Grabow W. O. K. // J. Appl. Microbiol. 2002. 92. P. 657–667.
43. Schmid E. N., von Recklinghausen G., Ansorg. R. // J. Med. Microbiol. 1990. 32. P. 
101–104.
44. Klieve A.V., Swain R.A.  // Appl. Environ. Microbiol. 59. P. 2299–2303.
45. Swain R.A., Nolan J.V., Klieve A.V. // Appl. Environ. Microbiol. 1996. 62. P.  994–997.
46. Furuse K., Sakurai T., Hirashima A., Katsuki M., Ando A., Watanbee I. // Appl. Envi-
ron. Microbiol. 1978. 35. P. 995–1002.REVIEWS
 VOL. 2  № 1 (4)  2010  | ACTA NATURAE | 71
47. Chibani-Chenoufi S., Sidoti J., Bruttin A. et al. // J. Bacteriol. 2004. 186. P. 8287–8294.
48. Ricca D.M., Cooney J.J. // J. Indust. Microbiol. Biotechnol. 2000. 24. P. 124–126.
49. Golomidova A., Kulikov E., Isaeva A., Manykin A., Letarov A. / / Appl. Environ. 
Microbiol. 2007. 73. P. 5975–5981.
50. Hintz H.F., Cymbaluk N.F. // Annu Rev. Nutr. 1994. 14. P. 243–267.
51. Yoshida T., Ellner S.P., Jones L.E. et al. // PloS. Biol. 2007. 5. P. 1868–1879.
52. Stephen A. M., Cummings J. H. // J. Med. Microbiol. 1980. 13. P. 45–56.
53. Iverson W. G., Mills N. F. // Appl. Environ. Microbiol. 1977. 33. P. 810–813.
54. Wiggins B.A., Alexander M. // Appl. Environ. Microbiol. 1985. 48. P. 19–23.
55. Brokhurst M.A., Bukcling A., Rainey P.B. // Proc. R Soc. 2005. B 272. P. 1385–1391.
56. Holmfeldt K., Middelboe M., Nybroe O., Riemann L. //Appl. Environ. Microbiol. 2007. 
73. P. 6730–6739.
57. Poullain V., Gandon S., Brokhurst M.A., Buckling A., Hochberg M.E. // Evolution. 
2008. 62(1). 1–11.
58. Weitz J.S., Hatman H., Levin S.A. //Proc. Natl. Acad. Sci. 2005. 102. P. 9535–9540.
59. Hoskisson P., Smith M.C.M. //Curr. Opin. Microbiol. 2007. 10. P. 396–400.
60. Pal C., Macia M., Oliver A., Schachar I., Buckling A. // Nature. 2009. 450. P. 1079–1081.
61. Sundin G.W., Weingard M.R. // FEMS Microbiol. Let. 2007. 277. P. 11–20.
62. LeClerc J.E., Li B., Payne W.L.,  Cebula T.A. // Science. 1996. 274. P. 1208–1211.
63. Milinovich G.J., Trott D.J., Burrell P.C. et al. // Environ. Microbiol. 2006. 8. P. 885–898.
64. Atterbury R. J., Dillon E., Swift C, et al. // Appl. Environ. Microbiol. 2005. 71. P. 
4885–4887.
65. Scott A.E., Timms A.R., Connerton P.L., El-Shibiny A., Connerton I.F. // Environ. 
Microbiol. 9. P. 2341–2353.
66. Scott A.E., Timms A.R., Connerton P.L. et al. // Plos. Biology. 2007. 3. P. 114.
67. Brussow H. // Microbiology.  2005. 151. P. 2133–2140.
68. Chibani-Chenoufi S., Sidoti J., Bruttin A. et al. // Antimicrob. Agents. Chemotherapy. 
2004. 48. P. 2558–2569.
69. Kasman L. // Virology. 2. P. 34.
70. Gabig M., Herman-Antosiewicz A., Kwiatkowska M. et al. // Microbiology. 2002. 148. 
P. 1533–1542.
71. Araujo R., Muniesa M., Méndez J. et al. // J. Virol. Meth. 2001. 93. P. 127–136.
72. Poulsen L.K., Licht T.R., Rang C., Krogfelt K.A., Molin. S. // J. Bacteriol. 1995. 
177:5840–5845.
73. Krogfelt K.A., Poulsen L.K., Molin S. // Infect. Immun. 1993. 61. P. 5029–5034.
74. Stryiak I., Kmet V., Spanova A. // Microbiologica. 1989. 12. P. 317–322.
75. Swain R.A., Nolan J.V., Klieve A.V. // Microbiology Australia. 1996. 17. A87(GWP.27).
76. Wells J.E., Russel J.B. // J. Dairy Sci. 1996. 79. P. 1487–1495.
77. Antonio M.A.D., Hawes S.E., Hillier S.L. // The J. Inf. Diseases. 1999. 180. P. 1950–1956.
78. Antonio M.A.D., Hillier S.L. // J. Clin. Microbiol. 2003. 41. P. 1881–1887.
79. Kiliç A.O., Pavlova S. I., Alpay S., Kiliç S.S., Tao L. (2001) // Clin. Diagn. Lab. Immunol. 
2001. 8. P. 31–39.
80. Martin R., Soberyn N., Escobedo S., Suarez J. // Int. Microbiol. 2009. 12. P. 131–136.
81. Blackwell A.L. // Sex Transm. Infect. 1999. 75. P. 352–353.
82. Fethers K.A., Fairley C.K., Hocking J.S., Gurrin L.C., Bradshaw C.S. // Clin. Infect. 
Dis. 2008. 47. P. 1426–1435.
83. Brown S.P., Le Chat L., De Paepe M., Taddei F. // Curr. Biol. 2006. 16. P. 2048–2052.
84. Kihara A., Akiyama Y., Ito K. (2001) // J. Biol.Chem. 2001. 276. P. 13695–13700.
85. Riipinen K.A., Raisanen L., Alatossava T. // J. Appl. Microbiol. 2007. 103. P. 2465–2475.
86. Pavlova S.I., Tao L. // Mutat. Res. 2000. 466. P. 57–62.
87. Tock M.R., Dryden D.T. // Curr. Opin. Microbiol. 2005. 8. P. 466–472.
88. Durmaz E., Klaenhammer T.R. //. J Bacteriol. 2007. 189. P. 1417–1425.
89. Fineran P.C., Blower T.R., Foulds I.J. et al. // Proc. Natl. Acad. Sci. U S A. 2009.106. 
P. 894–899.
90. Sorek R., Kunin V., Hugenholtz P. // Nat. Rev. Microbiol. 2008. 6. P. 181–186.
91. Hale C.R., Zhao P., Olson S. et al. // Cell. 2009. 139. P. 945–956.
92. Wiedenheft B., Zhou K., Jinek M., Coyle S.M., Ma W., Doudna J.A. // Structure. 2009. 
17. P. 904–912.
93. Bystricky V., Drahos V., Mulczyck M., Przondo-Hessek A., Slopeck S. // Acta Virol. 
1964. 176. P. 369–372.
94. Dennehy J.J., Friedenberg N.A., Yang Y.W., Turner P.E. // Ecol.Lett. 2007. 10. 
P. 230–240.
95. Fraser J.S., Maxwell K.L., Davidson A.R. // Curr. Opin. Microbiol. 2007. 10. P. 382–387.
96. Letarov A., Manival X., Desplats C., Krisch H.M. // J. Bacteriol. 2005. 187. P. 1055–1066.
97. Gallet R., Shao Y., Wang I. // BMC Evolutionary Biology. 2009. 9:241.
98. Dhillon E.K.S., Dhillon T.S., Lam Y.Y., Tsang A.H.C. // Appl. Environ. Microbiol. 1980. 
39. P. 1046–1053.
99. Miller R.V., Day M. Contribution of lysogeny, pseudolysogeny, and starvation to phage 
ecology. In S. T. Abedon (ed): Bacteriophage Ecology. Cambridge U. Press, Cambridge. 
2008. P. 114–143.
100. Dabrowska K., Switala-Jelen K., Opolski A., Weber-Dabrowska B. Gorski A. // 
J. Applied Microbiol. 2005. 98. P. 7–13.
101. Gorski A., Wazna E., Weber-Dabrowska B., Dabrowska K., Switala-Jelen K., Miedzy-
brodzki R. //. FEMS Immunol. Med. Microbiol. 2006. 46. P. 313–319.
102. Olivera A., Sereno R., Nicolau A., Azeredo J. // Poultry Sci. 2009. 88. P. 728–733.
103. Bogovazova G.G., Voroshilova N.N., Bondarenko V.M. // Zhurnal mikrobiologii, 
epidemiologii i immunobiologii. 1991. № 4. P. 5–8.
104. Perepanova T.S., Darbeeva O.S., Kotliarova G.A., et al. // Urologia I nephrologia. 
№ 5. P. 14–17.
105. Subbotin A.V., Funker M.G., Urman E.S. et al. // Use of a sextaphage in complex 
antibacterial treatment of induced pancreonecrosis. Zdorovye i obrazovanie: Materiali 
mezhdunarodnoy nauchno-prakticheskoy konferencii. Perm, 2006.  P. 191–197.
106. Tokarev M.V., Davidov M.I., Funker E.V. // Treatment of acute pyelonephritis using 
bacteriophages. // Aktualinie voprosi klinicheskoy medicini. Sbornik nauchnih trudov, 
posviaschenniy 130-letiu Permskoy GKB #6. Perm. 2005.
107. Constantini T.V., Putnam J.G., Sawada R. et al. // Surgery. 2009. 146. P. 206–212.
108. Duerr D.M., White S.J., Shluesener H.J. //. J. Virol. Methods. 2004. 116. P. 177–180.
109. Higgins L.M., Lambkin I., Donnelly G. et al. // Pharm. Res. 2004. 21. P. 695–705.
110. Kang S.K., Woo J.H., Kim M.K., Woo S.S., Choi J.H., Lee N.K., Choi Y.J. // J. Biotech-
nol. 2009. 135. P. 210–216.
111. Hamzeh-Mivehroud M., Mahmoudpour A., Rezazadeh H., Dastmalchi S. // Eur. J. 
Pharm. Biopharm. 2008. 70. P. 577–581.
112. Uchiyama J., Maeda Y., Takemura I. et al. // Microbiol. Immunol. 2009. 53. P. 301–304.
113. Dubos R., Straus J.H., Pierce C. // J. Exp. Med. 1943. 20. P. 161–168.
114. Raynaud A., Cloastre L., Bernard J. et al. // Vet. Microbiol. 1992. 30. P. 203–212.
115. Inchley C.J. // Clin. Exp. Immunol. 1969. 5. P. 173–187.
116. Appelmans R. Le bacteriophage dans l’organisme. Compt. Rend. Soc. de Biol. 1921. 
85. P. 722–724.
117. Vitiello C.L., Merril C. R., Adhya S. // Virus. Res. 2005. 114. P. 101–103.
118. Capparelli R., Parlato M., Borrielo G., Salvatore P., Iannelli D. // Antimicrobiol. 
Agents Chemother. 2007. 51. P. 2765–2773.
119. Capparelli R., Ventimiglia S., Roperto S., Fenizia D., Iannelli D. // Clin. Microbiol. 
Infect. 12. P. 248–253.
120. Kucharewicz-Krukowska A., Slopeck S. // Arch. Immunol. Ther. Exp. (Warsz) 1987. 
35. P. 553–561.
121. Adams M. Bacteriophages. М.: Izdatelstvo inostrannoy literaturi. 1961. P. 527.
122. Miedzybrodzki R., Switala-Jelen K., Fortuna W. et al. // Virus. Res. 2008. 131. 
P. 233–242.
123. Pajtasz-Piasecka E., Rossowska J., Dus D., Weber-Dabrowska B. et al. (2008) // Im-
munol. Let. 2008. 116. P. 24–32.
124. Przerwa A., Zimecki M., Switała-Jelen K. et al. // Med. Microbiol. Immunol. 2006. 
195. P. 143–150.
125. Dabrowska K., Zembala M., Boratynski J. et al. //Arch. Microbiol. 2007. 187. P. 489–98.
126. Rasmussen M., Jacobson M., Bjork L. // The J. Biol. Chem. 2003. 278. P. 32313–32316.
127. Cairns B., Timms A.R., Jansen V.A.A., Connerton I.F., Payne R.J.H. //. PLoS Pathog. 
2009. 5(1): e1000253. doi:10.1371/journal.ppat.1000253.
128. Vinga I., Sao-Jose C., Tavares P., Santos M. Bacteriophage entry in the host cell. In 
Modern bacteriophage biology and biotechnology. Wegrzyn G. ed. Research signpost, 
Kerala, India. 2006.
129. Kasman L., Kasman A., Westwater C., Dolan J., Schmidt M.G., Norris J.S. //. J. Virol. 
2002. 76. P. 5557–5564.
130. Macfarlane S., Dillon J.F. // J. Appl. Microbiol. 2007. 102. P. 1187–1196.
131. Anderson G.G., O’Toole G.A. // Curr. Top. Microbiol. Immunol.2008. 322. P. 85–105.
132. Azeredo J., Sutherland I.W. // Curr. Pharm. Biotechnol. 2008. 9. P. 261–266.
133. Cerca N., Olivera R., Azeredo J. // Lett. Appl. Microbiol. 2007. 45. P. 313–317.
134. Lu T.K., Collins J.J. // Proc. Natl. Acad. Sci. 2007. 104. P. 11197–11202.
135. Pearl S., Gabay C., Kishony R., Oppenheim A., Balaban N. // PLoS Biol. 2008. 6(5): 
e120. doi:10.1371/journal.pbio. 0060120.
136. Lewis K. // Curr. Top. Microbiol. Immunol. 2008. 322. P. 107–131.
137. Jikia D., Chkhaidze N., Imedashvili E. et al. Clin. Exp. Dermatol. 2005. 30. P. 23–26.
138. Bohannan B.J.M., Lenski R.E. // Ecology Lett. 3. P. 362–377.
139. Fischetti V.A. // Curr. Opin. Microbiol. 2008. 11. P. 393–400.
140. Smith H.W., Huggins M.B. // J. Gen. Microbiol. 1983. 133. P. 1111–1126.